Showing 431-440 of 2065 results for "".
Repairing the Ellipse; Resident Salary Update
https://practicaldermatology.com/youngmd-connect/resident-resource-center/repairing-the-ellipse-resident-salary-update/20414/Cutaneous Manifestations Associated with Nemolizumab
https://practicaldermatology.com/issues/september-2025/cutaneous-manifestations-associated-with-nemolizumab/37628/In the 2025 study by Sasaki et al entitled “Clinical characteristics and risk factors for cutaneous manifestations associated with nemolizumab in atopic dermatitis: a multicenter retrospective study in Japan,” nemolizumab-induced cutaneous eruptions were found to be relatively common, typically occuTopical Corticosteroids and Topical Calcineurin Inhibitors in Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/topical-corticosteroids-and-topical-calcineurin-inhibitors-atopic-dermatitis/29118/Analysis of a 2024 study by Gether et al., in which the authors compared the effectiveness of topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) in adults with atopic dermatitis (AD).What's Next in Aesthetic Medicine?
https://practicaldermatology.com/topics/practice-management/whats-next-in-aesthetic-medicine/20523/Insights on the future of cosmetic care from DermTube.com.Post-PHE Survival Guide for Dermatologists
https://practicaldermatology.com/topics/practice-management/post-phe-survival-guide-for-dermatologists/23914/Three things to know and do now that the PHE is over.It’s A Hit! CSF Takes to Music City
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/its-a-hit-csf-takes-to-music-city/23199/If you weren’t at the meeting in Nashville, here’s what you missed.Preparing for Private Equity: Benefits and Drawbacks
https://practicaldermatology.com/issues/september-2025/preparing-for-private-equity-benefits-and-drawbacks/37629/Over the past decade, the health care industry has emerged as a prime target for private equity (PE) investment.Don’t Pardon the Interruption
https://practicaldermatology.com/series/editors-message/dont-pardon-the-interruption/24021/A Growing Neuromodulator Market: Daxxify Approved
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/a-growing-neuromodualtor-market-daxxify-approved/23797/Revance Therapeutics’ DaxibotulinumtoxinA-lanm is now approved to treat glabellar lines.Dumbing Down of Dermatology By Evidence-Based Medicine
https://practicaldermatology.com/topics/practice-management/how-do-you-make-this-do-that/20593/